switzerlanden
Adjusting the Value factor for intangibles

Adjusting the Value factor for intangibles

19-02-2020 | From the field
The standard academic definition for the Value factor is the ratio of book-value-to market-value (B/M). This paper 1 observes that the performance of B/M has weakened substantially in recent decades, and argues that this deterioration is related to the growth of intangible assets unrecorded on balance sheets.
  • David Blitz
    David
    Blitz
    Chief Researcher

The author proposes an intangible-adjusted version of the B/M ratio to define value, which capitalizes the investments in knowledge capital and organizational capital that need to be treated as expenses in official financial statements. An example of an investment in knowledge capital is R&D, i.e. research and development.

The author finds that the intangible-adjusted B/M ratio outperforms the original ratio significantly, and also remained effective in recent decades. At Robeco’s quantitative research group, where we also like to think of ourselves as an asset to the firm rather than an expense, we are currently looking into this idea, and the initial results look promising indeed.

1 Park, H., 2019, ‘An Intangible-adjusted Book-to-market Ratio Still Predicts Stock Returns’, Critical Finance Review (forthcoming).

Now also follow us on Instagram
Now also follow us on Instagram
Follow
From the field
From the field

Our researchers publish many whitepapers based on their own empirical studies; they also follow quantitative research done by others.

Read all articles
Subjects related to this article are:
Logo

Disclaimer Robeco Switzerland Ltd.

The information contained on these pages is for marketing purposes and solely intended for Qualified Investors in accordance with the Swiss Collective Investment Schemes Act of 23 June 2006 (“CISA”) domiciled in Switzerland, Professional Clients in accordance with Annex II of the Markets in Financial Instruments Directive II (“MiFID II”) domiciled in the European Union und European Economic Area with a license to distribute / promote financial instruments in such capacity or herewith requesting respective information on products and services in their capacity as Professional Clients. 

The Funds are domiciled in Luxembourg and The Netherlands. ACOLIN Fund Services AG, postal address: Affolternstrasse 56, 8050 Zürich, acts as the Swiss representative of the Fund(s). UBS Switzerland AG, Bahnhofstrasse 45, 8001 Zurich, postal address: Europastrasse 2, P.O. Box, CH-8152 Opfikon, acts as the Swiss paying agent. The prospectus, the Key Investor Information Documents (KIIDs), the articles of association, the annual and semi-annual reports of the Fund(s) may be obtained, on simple request and free of charge, at the office of the Swiss representative ACOLIN Fund Services AG. The prospectuses are also available via the website www.robeco.ch. Some funds about which information is shown on these pages may fall outside the scope of the Swiss Collective Investment Schemes Act of 26 June 2006 (“CISA”) and therefore do not (need to) have a license from or registration with the Swiss Financial Market Supervisory Authority (FINMA). 

Some funds about which information is shown on this website may not be available in your domicile country. Please check the registration status in your respective domicile country. To view the RobecoSwitzerland Ltd. products that are registered/available in your country, please go to the respective Fund Selector, which can be found on this website and select your country of domicile. 

Neither information nor any opinion expressed on this website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco Switzerland Ltd. product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports. 

By clicking “I agree” you confirm that you/the company you represent falls under one of the above-mentioned categories of addressees and that you have read, understood and accept the terms of use for this website.

I Disagree